Results of the first clinical trial to combine two new targeted cancer drugs suggest that the combination may provide a powerful “one-two punch” against lung cancer, the nation’s leading cancer killer. The work, led by researchers at the Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and The University of Texas M.D. Anderson Cancer Center in Houston, was presented at the 40th annual meeting of the American Society of Clinical Oncology in New Orleans.
